# A U.S. jury finds Takeda Pharmaceutical liable for causing about $885 million in damages.

*biotech · news · 2026-05-19 · Devdiscourse*

## Key points

- A U.S. jury found Takeda liable for $885 million for delaying generic Amitiza via anticompetitive practices.
- The awarded damages could automatically triple under federal antitrust law, potentially reaching $2.47 billion.
- This is the first jury verdict holding a pharmaceutical company liable for pay-for-delay since the 2013 Supreme Court ruling.
- Takeda will revise its previous fiscal year financial statements to reflect possible litigation provisions.
- The settlement between Takeda, Sucampo, and Par delayed generic Amitiza by six years, per plaintiffs.

**Companies:** Takeda Pharmaceutical, CVS, Walgreens, Sucampo Pharmaceuticals
**Countries:** United States, Japan

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/law-order/3913535-update-4-takeda-engaged-in-antitrust-scheme-to-delay-generic-constipation-drug-us-jury-finds)

---

Canonical: https://newsio.io/n/8d670e86-7fe4-429a-a827-f9ee518820f9/a-u-s-jury-finds-takeda-pharmaceutical-liable-for-causing-about-885-million-in-d
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works